Discussion
A single oral dose of the experimental treatment deucrictibant rapidly brought hereditary angioedema (HAE) attacks under control, significantly shortening the time to symptom relief, stopping attacks from worsening sooner, and speeding complete symptom resolution compared with a placebo. That’s according to results from the now-completed Phase 3 RAPIDe-3 trial…